Biopharma firm Acumen's Q3 net loss narrows, beats estimates

Acumen Pharmaceuticals

12/11/2025 12:07

Overview

Acumen Q3 net income and income from operations beat analyst estimates

Company's cash expected to support operations into early 2027

R&D expenses decreased due to reduced CRO costs for ALTITUDE-AD trial

Outlook

Company expects topline results from ALTITUDE-AD study in late 2026

Company anticipates non-clinical data to inform EBD strategy in early 2026

Cash reserves expected to support operations into early 2027

Result Drivers

R&D EXPENSES - Decrease in R&D expenses attributed to reduced CRO costs for ALTITUDE-AD trial

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Beat
-$26.45 mln
-$35.46 mln (4 Analysts)
Q3 Income From Operations
Beat
-$26.51 mln
-$33.83 mln (4 Analysts)
Q3 Basic EPS
-$0.44
Q3 Operating Expenses
$26.51 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $9.50, about 79.3% above its November 11 closing price of $1.97

Press Release: ID:nGNX52ymd9

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)